Advertisement


Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer

2025 ASCO Annual Meeting

Advertisement

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer (LBA4). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Here at ASCO, we're presenting the results of the SERENA-6 study in the plenary session. SERENA-6 is a study for patients who've got metastatic advanced breast cancer that's hormone receptor-positive, HER2-negative on their first-line aromatase inhibitor and CDK4/6. We know in this setting, up to 40% of patients can acquire ESR1 mutations in their cancer as the key mechanism of resistance. We also know we can use liquid biopsies to detect these ESR1 mutations emerging long before disease progression. In SERENA-6, we recruited over 3,000 patients into surveillance with sequential liquid biopsies every two to three months to detect those ESR1 mutations at the earliest stages. 315 patients were then randomized to the standard of care, which was to continue AI and CDK4/6 inhibitor or to switch from AI to camizestrant and CDK4/6. Camizestrant is a next-generation oral SERD. It’s been designed specifically to target these estrogen receptor mutations as well as the wild-type ER. It completely inhibits ER signaling as well as degrades the mutant receptor. And what we then showed is that by switching to camizestrant, we over doubled progression-free survival in the study. And very importantly, 24 months after randomization, only 5% of patients in the control arm were without progression, whereas those who switched over to camizestrant when we detect an ESR1 mutation, 30% of them were without progression. And we're starting to see a real tail on the curve emerge. Also, we looked at quality of life and time to deterioration of quality of life in the study, and we saw a very substantial prolongation in the time to deterioration in quality of life—almost out to two years in the camizestrant group by switching ahead of disease progression. So in SERENA-6, we're trying to bring forward a new way of treating people with advanced hormone receptor-positive breast cancer to prolong first-line therapy. Currently, we don't know the optimal time to change therapy. We have to wait until disease progression. The tumor starts to grow on the scan again. But this can cause symptoms and it's often a real psychological blow for patients. And so what we are doing here is identifying much earlier exactly when the tumor is beginning to develop resistance to therapy and then switching to an effective therapy that targets those ESR1 mutations and keeps the patient well on first-line therapy for longer.

Related Videos

Gynecologic Cancers

Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer

Alicia Latham, MD, MS, of Memorial Sloan Kettering Cancer Center, discusses the feasibility of using Pap-derived ctDNA for the detection of sporadic and Lynch syndrome–associated endometrial cancer (Abstract 10503). 

Leukemia

Nitin Jain, MD, on Front-Line Therapies for CLL: Research Highlights From ASCO 2025

Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual Meeting. 

Prostate Cancer

Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?

Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARANOTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients with metastatic hormone-sensitive prostate cancer (Abstract 5004). 

Prostate Cancer

Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013). 

Shahzad Raza, MD, on Relapsed or Refractory AL Amyloidosis: First U.S. Trial of CAR T-Cell Therapy

Shahzad Raza, MD, of the Cleveland Clinic, reviews safety and efficacy data from Nexicart-2, the first U.S.-based trial of chimeric antigen receptor (CAR) T-cell therapy—an agent known as Nxc-201—in patients with relapsed or refractory light chain (AL) amyloidosis (Abstract 7508). 

Advertisement

Advertisement




Advertisement